Evidence map›Paper›PMID 41066744›Full record

ArticleJournal of food and drug analysis2025

Yi-Qi-Xuan-Fei Formula ameliorate chronic obstructive pulmonary disease by remodeling lung and intestinal florase in rat models.

Si-Si Han, Li-Yun Song, Peng-Tao Liang, Yin-Ying Wang, Yi Ying, Li Li, Jia-Li Yuan, Zhong-Shan Yang

Erratum issuedAbstract read
In one paragraph

Article in Journal of food and drug analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Si-Si HanYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Li-Yun SongYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Peng-Tao LiangYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Yin-Ying WangYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Yi YingYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Li LiYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Jia-Li YuanYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Zhong-Shan YangYunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming, 650500, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by various pathological lesions and an imbalance in the microflora. The Yi-Qi-Xuan-Fei Formula (YQXF) is a clinically effective formula with pharmacological potential to delay the progression of COPD. This study aims to explore the relationship between the therapeutic mechanism of YQXF and the microflora in COPD. Our study found that YQXF reduces inflammatory injury and inflammatory cell infiltration in lung tissue, repairs the intestinal mucosal barrier, and enhances immune function. Additionally, YQXF regulates the pulmonary and intestinal flora by increasing the abundance of Alloprevotella, Roseburia, Oscillibacter, and Lactobacillus, while reducing the abundance of Fusobacterium, Escherichia/Shigella, and Clostridium sensu stricto. Moreover, YQXF elevates the levels of short-chain fatty acids, which are produced by the intestinal flora. In conclusion, our findings demonstrate that YQXF reduces inflammation levels in lung tissue and repairs the intestinal barrier in COPD rats. Furthermore, the anti-inflammatory and tissue damage prevention effects of YQXF are based on its intervention in the pulmonary and intestinal flora. These findings provide valuable insights into the fundamental mechanism of the herbal formula YQXF and suggest that specifically targeting the intestinal flora could be a potential therapeutic approach for COPD.

Indexed as

Drugs, Chinese HerbalGastrointestinal MicrobiomeLungPulmonary Disease, Chronic ObstructiveAnimalsBacteriaDisease Models, AnimalHumansMaleRatsRats, Sprague-DawleyDrugs, Chinese Herbal

Identifiers

PMID41066744
PMCPMC12510709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.